Paraneoplastic syndromes associated with lung cancer

World Journal of Clinical Oncology

Volumn 5, Issue 3, 2014, Pages 197-223

  Kanaji, Nobuhiro ^a   Watanabe, Naoki ^a   Kita, Nobuyuki ^a   Bandoh, Shuji ^a   Tadokoro, Akira ^a   Ishii, Tomoya ^a   Dobashi, Hiroaki ^a   Matsunaga, Takuya ^a  

^a KAGAWA UNIVERSITY   (Japan)

Author keywords

Diagnosis; Endocrine; Hematologic; Neurologic; Non small cell lung cancer; Paraneoplastic syndrome; Small cell lung cancer; Symptom; Treatment; Trousseau's syndrome

Indexed keywords

EID: 84916204173     PISSN: None     EISSN: 22184333     Source Type: Journal    
DOI: 10.5306/wjco.v5.i3.197     Document Type: Review

References (326)

1. Spiro SG, Gould MK, Colice GL. Initial evaluation of the patient with lung cancer: symptoms, signs, laboratory tests, and paraneoplastic syndromes: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest 2007; 132: 149S-160S [PMID: 17873166 DOI: 10.1378/chest.07-1358]
2. Pelosof LC, Gerber DE. Paraneoplastic syndromes: An approach to diagnosis and treatment. Mayo Clin Proc 2010; 85: 838-854 [PMID: 20810794 DOI: 10.4065/mcp.2010.0099]
3. McClelland MT. Paraneoplastic syndromes related to lung cancer. Clin J Oncol Nurs 2010; 14: 357-364 [PMID: 20529797 DOI: 10.1188/10.CJON.357-364]
4. Mazzone PJ, Arroliga AC. Endocrine paraneoplastic syndromes in lung cancer. Curr Opin Pulm Med 2003; 9: 313-320 [PMID: 12806246 DOI: 10.1097/00063198-200307000-00012]
5. Clines GA. Mechanisms and treatment of hypercalcemia of malignancy. Curr Opin Endocrinol Diabetes Obes 2011; 18: 339-346 [PMID: 21897221 DOI: 10.1097/MED.0b013e32834b4401]
6. Yoshimoto K, Yamasaki R, Sakai H, Tezuka U, Takahashi M, Iizuka M, Sekiya T, Saito S. Ectopic production of parathyroid hormone by small cell lung cancer in a patient with hypercalcemia. J Clin Endocrinol Metab 1989; 68: 976-981 [PMID: 2541161 DOI: 10.1210/jcem-68-5-976]
7. Nielsen PK, Rasmussen AK, Feldt-Rasmussen U, Brandt M, Christensen L, Olgaard K. Ectopic production of intact parathyroid hormone by a squamous cell lung carcinoma in vivo and in vitro. J Clin Endocrinol Metab 1996; 81: 3793-3796 [PMID: 8855839]
8. Radulescu D, Pripon S, Bunea D, Ciuleanu TE, Radulescu LI. Endocrine paraneoplastic syndromes in small cell lung carcinoma. Two case reports. J BUON 2007; 12: 411-414 [PMID: 17918299]
9. Hiraki A, Ueoka H, Takata I, Gemba K, Bessho A, Segawa Y, Kiura K, Eguchi K, Yoneda T, Tanimoto M, Harada M. Hypercalcemia-leukocytosis syndrome associated with lung cancer. Lung Cancer 2004; 43: 301-307 [PMID: 15165088 DOI: 10.1016/j.lungcan.2003.09.006]
10. Ma XT, Yu LW, Fu J. Paraneoplastic syndromes of hypercalcemia and leukocytosis associated with colonic metastases from squamous cell carcinoma of the lung. Int J Colorectal Dis 2008; 23: 129-130 [PMID: 17211655 DOI: 10.1007/s00384-006-0256-9]
11. Suva LJ, Winslow GA, Wettenhall RE, Hammonds RG, Moseley JM, Diefenbach-Jagger H, Rodda CP, Kemp BE, Rodriguez H, Chen EY. A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression. Science 1987; 237: 893-896 [PMID: 3616618 DOI: 10.1126/science.3616618]
12. Pioszak AA, Parker NR, Gardella TJ, Xu HE. Structural basis for parathyroid hormone-related protein binding to the parathyroid hormone receptor and design of conformationselective peptides. J Biol Chem 2009; 284: 28382-28391 [PMID: 19674967 DOI: 10.1074/jbc.M109.022905]
13. Lorch G, Gilmore JL, Koltz PF, Gonterman RM, Laughner R, Lewis DA, Konger RL, Nadella KS, Toribio RE, Rosol TJ, Foley J. Inhibition of epidermal growth factor receptor signalling reduces hypercalcaemia induced by human lung squamous-cell carcinoma in athymic mice. Br J Cancer 2007; 97: 183-193 [PMID: 17533397]
14. Gilmore JL, Gonterman RM, Menon K, Lorch G, Riese DJ, Robling A, Foley J. Reconstitution of amphiregulin-epidermal growth factor receptor signaling in lung squamous cell carcinomas activates PTHrP gene expression and contributes to cancer-mediated diseases of the bone. Mol Cancer Res 2009; 7: 1714-1728 [PMID: 19825997 DOI: 10.1158/1541-7786. MCR-09-0131]
15. Takai E, Yano T, Iguchi H, Fukuyama Y, Yokoyama H, Asoh H, Ichinose Y. Tumor-induced hypercalcemia and parathyroid hormone-related protein in lung carcinoma. Cancer 1996; 78: 1384-1387 [PMID: 8839542 DOI: 10.1002/(S ICI)1097-0142(19961001)78: 73.0.CO; 2-L]71384: : AID-CNCR33.0.CO; 2-L
16. Stewart AF. Clinical practice. Hypercalcemia associated with cancer. N Engl J Med 2005; 352: 373-379 [PMID: 15673803 DOI: 10.1056/NEJMcp042806]
17. Hussain A, Adnan A, El-Hasani S. Small cell carcinoma of the lung presented as acute pancreatitis. Case report and review of the literature. JOP 2012; 13: 702-704 [PMID: 23183407 DOI: 10.6092/1590-8577/1181]
18. Dodwell DJ, Abbas SK, Morton AR, Howell A. Parathyroid hormone-related protein(50-69) and response to pamidronate therapy for tumour-induced hypercalcaemia. Eur J Cancer 1991; 27: 1629-1633 [PMID: 1782072 DOI: 10.1016/02 77-5379(91)90431-C]
19. Silva OL, Becker KL. Salmon calcitonin in the treatment of hypercalcemia. Arch Intern Med 1973; 132: 337-339 [PMID: 4798763 DOI: 10.1001/archinte.1973.03650090019004]
20. Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study. J Clin Oncol 2010; 28: 5132-5139 [PMID: 21060033 DOI: 10.1200/JCO.2010.29.7101]
21. Ost DE, Yeung SC, Tanoue LT, Gould MK. Clinical and organizational factors in the initial evaluation of patients with lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013; 143: e121S-e141S [PMID: 23649435 DOI: 10.1378/chest.12-2352]
22. List AF, Hainsworth JD, Davis BW, Hande KR, Greco FA, Johnson DH. The syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in small-cell lung cancer. J Clin Oncol 1986; 4: 1191-1198 [PMID: 3016206]
23. Hainsworth JD, Workman R, Greco FA. Management of the syndrome of inappropriate antidiuretic hormone secretion in small cell lung cancer. Cancer 1983; 51: 161-165 [PMID: 6295592 DOI: 10.1002/1097-0142(19830101)51161: : AIDCNCR2820510131: 1 3.0.CO; 2-P]
24. Lokich JJ. The frequency and clinical biology of the ectopic hormone syndromes of small cell carcinoma. Cancer 1982; 50: 2111-2114 [PMID: 6290023 DOI: 10.1002/1097-0142(1982 1115)502111: : AID-CNCR2820501023: 103.0.CO; 2-O]
25. Vanhees SL, Paridaens R, Vansteenkiste JF. Syndrome of inappropriate antidiuretic hormone associated with chemotherapy-induced tumour lysis in small-cell lung cancer: case report and literature review. Ann Oncol 2000; 11: 1061-1065 [PMID: 11038047 DOI: 10.1023/A: 1008369932384]
26. Monsieur I, Meysman M, Noppen M, de Greve J, Delhove O, Velckeniers B, Jacobvitz D, Vincken W. Non-small-cell lung cancer with multiple paraneoplastic syndromes. Eur Respir J 1995; 8: 1231-1234 [PMID: 7589410 DOI: 10.1183/09031936.9 5.08071231]
27. Tho LM, Ferry DR. Is the paraneoplastic syndrome of inappropriate antidiuretic hormone secretion in lung cancer always attributable to the small cell variety? Postgrad Med J 2005; 81: e17 [PMID: 16272226 DOI: 10.1136/pgmj.2005.036889]
28. McDonald P, Lane C, Rojas GE, Masood A. Syndrome of inappropriate anti-diuretic hormone in non-small cell lung carcinoma: A case report. Ecancermedicalscience 2012; 6: 279 [PMID: 23233867 DOI: 10.3332/ecancer.2012.279]
29. Gross AJ, Steinberg SM, Reilly JG, Bliss DP, Brennan J, Le PT, Simmons A, Phelps R, Mulshine JL, Ihde DC. Atrial natriuretic factor and arginine vasopressin production in tumor cell lines from patients with lung cancer and their relationship to serum sodium. Cancer Res 1993; 53: 67-74 [PMID: 8380126]
30. Hansen O, Sørensen P, Hansen KH. The occurrence of hyponatremia in SCLC and the influence on prognosis: A retrospective study of 453 patients treated in a single institution in a 10-year period. Lung Cancer 2010; 68: 111-114 [PMID: 19535164 DOI: 10.1016/j.lungcan.2009.05.015]
31. Kamoi K, Ebe T, Hasegawa A, Sato F, Takato H, Iwamoto H, Kaneko H, Ishibashi M, Yamaji T. Hyponatremia in small cell lung cancer. Mechanisms not involving inappropriate ADH secretion. Cancer 1987; 60: 1089-1093 [PMID: 3038297 DOI: 10.1002/1097-0142(19870901)60: 1089: : AIDCNCR28206005285 3.0.CO; 2-U]
32. Bliss DP, Battey JF, Linnoila RI, Birrer MJ, Gazdar AF, Johnson BE. Expression of the atrial natriuretic factor gene in small cell lung cancer tumors and tumor cell lines. J Natl Cancer Inst 1990; 82: 305-310 [PMID: 2153841 DOI: 10.1093/jnci/82.4.305]
33. Campling BG, Sarda IR, Baer KA, Pang SC, Baker HM, Lofters WS, Flynn TG. Secretion of atrial natriuretic peptide and vasopressin by small cell lung cancer. Cancer 1995; 75: 2442-2451 [PMID: 7736387 DOI: 10.1002/1097-0142(1995051 5)752442: : AID-CNCR2820751009: 103.0.CO; 2-Q]
34. Radulescu D, Bunea D, Pripon S, Duncea C, Radulescu L. Severe paraneoplastic hyponatremia and hypoosmolality in a patient with small-cell lung carcinoma: syndrome of inappropriate antidiuretic hormone secretion versus atrial natriuretic peptide or both? Clin Lung Cancer 2007; 8: 392-395 [PMID: 17562242 DOI: 10.3816/CLC.2007.n.022]
35. Kamoi K, Ebe T, Kobayashi O, Ishida M, Sato F, Arai O, Tamura T, Takagi A, Yamada A, Ishibashi M. Atrial natriuretic peptide in patients with the syndrome of inappropriate antidiuretic hormone secretion and with diabetes insipidus. J Clin Endocrinol Metab 1990; 70: 1385-1390 [PMID: 2139879 DOI: 10.1210/jcem-70-5-1385]
36. Cogan E, Debiève MF, Philipart I, Pepersack T, Abramow M. High plasma levels of atrial natriuretic factor in SIADH. N Engl J Med 1986; 314: 1258-1259 [PMID: 2939346 DOI: 10.1056/NEJM198605083141921]
37. Donckier JE, Meunier HT, Ketelslegers JM, Lambert AE. Atrial natriuretic peptide and the syndrome of inappropriate secretion of antidiuretic hormone. Ann Intern Med 1986; 105: 795-796 [PMID: 2945506 DOI: 10.7326/0003-4819-105-5-795-2]
38. Ellison DH, Berl T. Clinical practice. The syndrome of inappropriate antidiuresis. N Engl J Med 2007; 356: 2064-2072 [PMID: 17507705 DOI: 10.1056/NEJMcp066837]
39. Raftopoulos H. Diagnosis and management of hyponatremia in cancer patients. Support Care Cancer 2007; 15: 1341-1347 [PMID: 17701059 DOI: 10.1007/s00520-007-0309-9]
40. Saintigny P, Chouahnia K, Cohen R, Pailler MC, Brechot JM, Morere JF, Breau JL. Tumor lysis associated with sudden onset of syndrome of inappropriate antidiuretic hormone secretion. Clin Lung Cancer 2007; 8: 282-284 [PMID: 17311695 DOI: 10.3816/CLC.2007.n.008]
41. Vaidya C, Ho W, Freda BJ. Management of hyponatremia: providing treatment and avoiding harm. Cleve Clin J Med 2010; 77: 715-726 [PMID: 20889809 DOI: 10.3949/ccjm.77a.08051]
42. De Troyer A. Demeclocycline. Treatment for syndrome of inappropriate antidiuretic hormone secretion. JAMA 1977; 237: 2723-2726 [PMID: 194065 DOI: 10.1001/jama.1977.0327 0520033016]
43. Tahara A, Saito M, Sugimoto T, Tomura Y, Wada K, Kusayama T, Tsukada J, Ishii N, Yatsu T, Uchida W, Tanaka A. Pharmacological characterization of YM087, a potent, nonpeptide human vasopressin V1A and V2 receptor antagonist. Naunyn Schmiedebergs Arch Pharmacol 1998; 357: 63-69 [PMID: 9459574 DOI: 10.1007/PL00005139]
44. Miyazaki T, Fujiki H, Yamamura Y, Nakamura S, Mori T. Tolvaptan, an orally active vasopressin V(2)-receptor antagonist-pharmacology and clinical trials. Cardiovasc Drug Rev 2007; 25: 1-13 [PMID: 17445084 DOI: 10.1111/j.1527-3466.2007.00001.x]
45. Kenz S, Haas CS, Werth SC, Bohnet S, Brabant G. High sensitivity to tolvaptan in paraneoplastic syndrome of inappropriate ADH secretion (SIADH). Ann Oncol 2011; 22: 2696 [PMID: 22021821 DOI: 10.1093/annonc/mdr431]
46. Spinazzé S, Schrijvers D. Metabolic emergencies. Crit Rev Oncol Hematol 2006; 58: 79-89 [PMID: 16337807 DOI: 10.1016/j.critrevonc.2005.04.004]
47. Boscaro M, Barzon L, Fallo F, Sonino N. Cushings syndrome. Lancet 2001; 357: 783-791 [PMID: 11253984 DOI: 10.1016/S0140-6736(00)04172-6]
48. Auchus RJ, Mastorakos G, Friedman TC, Chrousos GP. Corticotropin-releasing hormone production by a small cell carcinoma in a patient with ACTH-dependent Cushing s syndrome. J Endocrinol Invest 1994; 17: 447-452 [PMID: 7930390 DOI: 10.1007/BF03347737]
49. Shahani S, Nudelman RJ, Nalini R, Kim HS, Samson SL. Ectopic corticotropin-releasing hormone (CRH) syndrome from metastatic small cell carcinoma: A case report and review of the literature. Diagn Pathol 2010; 5: 56 [PMID: 20807418 DOI: 10.1186/1746-1596-5-56]
50. Morandi U, Casali C, Rossi G. Bronchial typical carcinoid tumors. Semin Thorac Cardiovasc Surg 2006; 18: 191-198 [PMID: 17185178 DOI: 10.1053/j.semtcvs.2006.08.005]
51. Barbosa SL, Rodien P, Leboulleux S, Niccoli-Sire P, Kraimps JL, Caron P, Archambeaud-Mouveroux F, Conte-Devolx B, Rohmer V. Ectopic adrenocorticotropic hormone-syndrome in medullary carcinoma of the thyroid: A retrospective analysis and review of the literature. Thyroid 2005; 15: 618-623 [PMID: 16029131 DOI: 10.1089/thy.2005.15.618]
52. Wajchenberg BL, Mendonca BB, Liberman B, Pereira MA, Carneiro PC, Wakamatsu A, Kirschner MA. Ectopic adrenocorticotropic hormone syndrome. Endocr Rev 1994; 15: 752-787 [PMID: 7705280]
53. Shepherd FA, Laskey J, Evans WK, Goss PE, Johansen E, Khamsi F. Cushings syndrome associated with ectopic corticotropin production and small-cell lung cancer. J Clin Oncol 1992; 10: 21-27 [PMID: 1309381]
54. Delisle L, Boyer MJ, Warr D, Killinger D, Payne D, Yeoh JL, Feld R. Ectopic corticotropin syndrome and small-cell carcinoma of the lung. Clinical features, outcome, and complications. Arch Intern Med 1993; 153: 746-752 [PMID: 8383484 DOI: 10.1001/archinte.1993.00410060054009]
55. Gewirtz G, Yalow RS. Ectopic ACTH production in carcinoma of the lung. J Clin Invest 1974; 53: 1022-1032 [PMID: 4360854 DOI: 10.1172/JCI107639]
56. Sarid N, Osher E, Gat A, Hoffman M, Oster HS. Cushing s syndrome as a harbinger of relapsed nonsmall cell lung cancer. Isr Med Assoc J 2012; 14: 523-524 [PMID: 22977976]
57. Collichio FA, Woolf PD, Brower M. Management of patients with small cell carcinoma and the syndrome of ectopic corticotropin secretion. Cancer 1994; 73: 1361-1367 [PMID: 8111702 DOI: 10.1002/1097-0142(19940301)731361: : AID-CNCR2820730509: 53.0.CO; 2-J]
58. Imura H, Matsukura S, Yamamoto H, Hirata Y, Nakai Y. Studies on ectopic ACTH-producing tumors. II. Clinical and biochemical features of 30 cases. Cancer 1975; 35: 1430-1437 [PMID: 164276 DOI: 10.1002/1097-0142(197505)351430: : AID-CNCR2820350529: 53.0.CO; 2-O]
59. Dimopoulos MA, Fernandez JF, Samaan NA, Holoye PY, Vassilopoulou-Sellin R. Paraneoplastic Cushings syndrome as an adverse prognostic factor in patients who die early with small cell lung cancer. Cancer 1992; 69: 66-71 [PMID: 1309310 DOI: 10.1002/1097-0142(19920101)69: 66: : AIDCNCR2820690113 1 3.0.CO; 2-2]
60. Guignat L, Bertherat J. The diagnosis of Cushings syndrome: An Endocrine Society Clinical Practice Guideline: commentary from a European perspective. Eur J Endocrinol 2010; 163: 9-13 [PMID: 20375177 DOI: 10.1530/EJE-09-0627]
61. Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage MO, Stewart PM, Montori VM. The diagnosis of Cushings syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008; 93: 1526-1540 [PMID: 18334580 DOI: 10.1210/jc.2008-0125]
62. Flack MR, Oldfield EH, Cutler GB, Zweig MH, Malley JD, Chrousos GP, Loriaux DL, Nieman LK. Urine free cortisol in the high-dose dexamethasone suppression test for the differential diagnosis of the Cushing syndrome. Ann Intern Med 1992; 116: 211-217 [PMID: 1728204 DOI: 10.7326/0003-4 819-116-3-211]
63. Newell-Price J, Trainer P, Besser M, Grossman A. The diagnosis and differential diagnosis of Cushings syndrome and pseudo-Cushings states. Endocr Rev 1998; 19: 647-672 [PMID: 9793762]
64. Kaye TB, Crapo L. The Cushing syndrome: An update on diagnostic tests. Ann Intern Med 1990; 112: 434-444 [PMID: 2178536 DOI: 10.7326/0003-4819-76-3-112-6-434]
65. Invitti C, Pecori Giraldi F, de Martin M, Cavagnini F. Diagnosis and management of Cushings syndrome: results of an Italian multicentre study. Study Group of the Italian Society of Endocrinology on the Pathophysiology of the Hypothalamic-Pituitary-Adrenal Axis. J Clin Endocrinol Metab 1999; 84: 440-448 [PMID: 10022398]
66. Ilias I, Torpy DJ, Pacak K, Mullen N, Wesley RA, Nieman LK. Cushings syndrome due to ectopic corticotropin secretion: Twenty years experience at the National Institutes of Health. J Clin Endocrinol Metab 2005; 90: 4955-4962 [PMID: 15914534 DOI: 10.1210/jc.2004-2527]
67. Salgado LR, Fragoso MC, Knoepfelmacher M, Machado MC, Domenice S, Pereira MA, de Mendonça BB. Ectopic ACTH syndrome: our experience with 25 cases. Eur J Endocrinol 2006; 155: 725-733 [PMID: 17062889 DOI: 10.1530/eje.1.02278]
68. Alexandraki KI, Grossman AB. The ectopic ACTH syndrome. Rev Endocr Metab Disord 2010; 11: 117-126 [PMID: 20544290 DOI: 10.1007/s11154-010-9139-z]
69. Torpy DJ, Chen CC, Mullen N, Doppman JL, Carrasquillo JA, Chrousos GP, Nieman LK. Lack of utility of (111)Inpentetreotide scintigraphy in localizing ectopic ACTH producing tumors: follow-up of 18 patients. J Clin Endocrinol Metab 1999; 84: 1186-1192 [PMID: 10199751 DOI: 10.1210/jcem.84.4.5576]
70. Nieman LK. Medical therapy of Cushings disease. Pituitary 2002; 5: 77-82 [PMID: 12675504 DOI: 10.1023/A: 1022308429992]
71. Duquenne M, Dousset B, Weryha G, Fade-Schneller O, Duriez T, Anthoine D, Leclere J, Hartemann P. Paradoxical effect of octreotide in neoplastic inappropriate corticotropin secretion. Lancet 1991; 338: 1407-1408 [PMID: 1682776 DOI: 10.1016/0140-6736(91)92293-B]
72. Cheung NW, Boyages SC. Failure of somatostatin analogue to control Cushings syndrome in two cases of ACTHproducing carcinoid tumours. Clin Endocrinol (Oxf) 1992; 36: 361-367 [PMID: 1424169 DOI: 10.1111/j.1365-2265.1992.Tb01461.x]
73. Nauck MA, Reinecke M, Perren A, Frystyk J, Berishvili G, Zwimpfer C, Figge AM, Flyvbjerg A, Lankisch PG, Blum WF, Klöppel G, Schmiegel W, Zapf J. Hypoglycemia due to paraneoplastic secretion of insulin-like growth factor-I in a patient with metastasizing large-cell carcinoma of the lung. J Clin Endocrinol Metab 2007; 92: 1600-1605 [PMID: 17299065 DOI: 10.1210/jc.2006-2573]
74. Baxter RC, Holman SR, Corbould A, Stranks S, Ho PJ, Braund W. Regulation of the insulin-like growth factors and their binding proteins by glucocorticoid and growth hormone in nonislet cell tumor hypoglycemia. J Clin Endocrinol Metab 1995; 80: 2700-2708 [PMID: 7545698]
75. Zapf J, Futo E, Peter M, Froesch ER. Can big" insulin-like growth factor II in serum of tumor patients account for the development of extrapancreatic tumor hypoglycemia? J Clin Invest 1992; 90: 2574-2584 [PMID: 1281841 DOI: 10.1172/JCI116152]
76. Shames JM, Dhurandhar NR, Blackard WG. Insulin-secreting bronchial carcinoid tumor with widespread metastases. Am J Med 1968; 44: 632-637 [PMID: 4296076 DOI: 10.1016/00 02-9343(68)90065-X]
77. Teale JD, Marks V. Glucocorticoid therapy suppresses abnormal secretion of big IGF-II by non-islet cell tu-mours inducing hypoglycaemia (NICTH). Clin Endocrinol (Oxf) 1998; 49: 491-498 [PMID: 9876347 DOI: 10.1046/j.1365-2265.1998.00564.x]
78. Hoff AO, Vassilopoulou-Sellin R. The role of glucagon administration in the diagnosis and treatment of patients with tumor hypoglycemia. Cancer 1998; 82: 1585-1592 [PMID: 9554538 DOI: 10.1002/(SICI)1097-0142(19980415)821585: : AID-CNCR22: 83.0.CO; 2-#]
79. Faglia G, Arosio M, Bazzoni N. Ectopic acromegaly. Endocrinol Metab Clin North Am 1992; 21: 575-595 [PMID: 1521513]
80. Biswal S, Srinivasan B, Dutta P, Ranjan P, Vaiphei K, Singh RS, Thingnam SS. Acromegaly caused by ectopic growth hormone: A rare manifestation of a bronchial carcinoid. Ann Thorac Surg 2008; 85: 330-332 [PMID: 18154841]
81. Melmed S. Extrapituitary acromegaly. Endocrinol Metab Clin North Am 1991; 20: 507-518 [PMID: 1935918]
82. Doga M, Bonadonna S, Burattin A, Giustina A. Ectopic secretion of growth hormone-releasing hormone (GHRH) in neuroendocrine tumors: relevant clinical aspects. Ann Oncol 2001; 12 Suppl 2: S89-S94 [PMID: 11762359 DOI: 10.1093/annonc/12.suppl-2.S89]
83. Motoi N, Kishi K, Fujii T, Tsuboi E, Ohashi K, Yoshimura K. Multiple bronchioloalveolar carcinomas in acromegaly: A potential role of insulin-like growth factor I in carcinogenesis. Lung Cancer 2006; 54: 247-253 [PMID: 16942817 DOI: 10.1016/j.lungcan.2006.07.011]
84. El Aziz S, Chadli A, Obbiba A, El Ghomari H, Farouqi A. Pulmonary epidermoid carcinoma in a patient with acromegaly: A rare entity. Pan Afr Med J 2012; 12: 27 [PMID: 22891085]
85. Phillips JD, Yeldandi A, Blum M, de Hoyos A. Bronchial carcinoid secreting insulin-like growth factor-1 with acromegalic features. Ann Thorac Surg 2009; 88: 1350-1352 [PMID: 19766843 DOI: 10.1016/j.athoracsur.2009.02.042]
86. Athanassiadi K, Exarchos D, Tsagarakis S, Bellenis I. Acromegaly caused by ectopic growth hormone-releasing hormone secretion by a carcinoid bronchial tumor: A rare entity. J Thorac Cardiovasc Surg 2004; 128: 631-632 [PMID: 15457172 DOI: 10.1016/j.jtcvs.2004.02.033]
87. Gudbjartsson T, Agnarsson BA, Palsson PS, Johannesson A. Acromegaly caused by ectopic growth hormone-releasing hormone production from a bronchial carcinoid tumor. Thorac Cardiovasc Surg 2011; 59: 184-185 [PMID: 21480145 DOI: 10.1055/s-0030-1250341]
88. Drange MR, Melmed S. Long-Acting lanreotide induces clinical and biochemical remission of acromegaly caused by disseminated growth hormone-releasing hormone-secreting carcinoid. J Clin Endocrinol Metab 1998; 83: 3104-3109 [PMID: 9745411 DOI: 10.1210/jcem.83.9.5088]
89. Butler PW, Cochran CS, Merino MJ, Nguyen DM, Schrump DS, Gorden P. Ectopic growth hormone-releasing hormone secretion by a bronchial carcinoid tumor: clinical experience following tumor resection and long-Acting octreotide therapy. Pituitary 2012; 15: 260-265 [PMID: 20379782 DOI: 10.1007/s11102-010-0226-7]
90. van Hoek M, Hofland LJ, de Rijke YB, van Nederveen FH, de Krijger RR, van Koetsveld PM, Lamberts SW, van der Lely AJ, de Herder WW, Feelders RA. Effects of somatostatin analogs on a growth hormone-releasing hormone secreting bronchial carcinoid, in vivo and in vitro studies. J Clin Endocrinol Metab 2009; 94: 428-433 [PMID: 19017754 DOI: 10.1210/jc.2008-1712]
91. de Jager CM, de Heide LJ, van den Berg G, Wolthuis A, van Schelven WD. Acromegaly caused by a growth hormone-releasing hormone secreting carcinoid tumour of the lung: The effect of octreotide treatment. Neth J Med 2007; 65: 263-266 [PMID: 17656813]
92. Honnorat J, Antoine JC. Paraneoplastic neurological syndromes. Orphanet J Rare Dis 2007; 2: 22 [PMID: 17480225 DOI: 10.1186/1750-1172-2-22]
93. Graus F, Delattre JY, Antoine JC, Dalmau J, Giometto B, Grisold W, Honnorat J, Smitt PS, Vedeler Ch, Verschuuren JJ, Vincent A, Voltz R. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 2004; 75: 1135-1140 [PMID: 15258215 DOI: 10.1136/jnnp.2003.034447]
94. Monstad SE, Knudsen A, Salvesen HB, Aarseth JH, Vedeler CA. Onconeural antibodies in sera from patients with various types of tumours. Cancer Immunol Immunother 2009; 58: 1795-1800 [PMID: 19294382 DOI: 10.1007/s00262-009-0690-y]
95. Dalmau J, Rosenfeld MR. Paraneoplastic syndromes of the CNS. Lancet Neurol 2008; 7: 327-340 [PMID: 18339348 DOI: 10.1016/S1474-4422(08)70060-7]
96. Darnell RB, Posner JB. Paraneoplastic syndromes involving the nervous system. N Engl J Med 2003; 349: 1543-1554 [PMID: 14561798 DOI: 10.1056/NEJMra023009]
97. Elrington GM, Murray NM, Spiro SG, Newsom-Davis J. Neurological paraneoplastic syndromes in patients with small cell lung cancer. A prospective survey of 150 patients. J Neurol Neurosurg Psychiatry 1991; 54: 764-767 [PMID: 1659614 DOI: 10.1136/jnnp.54.9.764]
98. Keime-Guibert F, Graus F, Fleury A, René R, Honnorat J, Broet P, Delattre JY. Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatry 2000; 68: 479-482 [PMID: 10727484 DOI: 10.1136/jnnp.68.4.479]
99. Vernino S, ONeill BP, Marks RS, OFallon JR, Kimmel DW. Immunomodulatory treatment trial for paraneoplastic neurological disorders. Neuro Oncol 2004; 6: 55-62 [PMID: 14769141 DOI: 10.1215/S1152851703000395]
100. Hirano S, Nakajima Y, Morino E, Fujikura Y, Mochizuki M, Takeda Y, Sugiyama H, Kobayashi N, Tanaka K, Kudo K. A case of spontaneous regression of small cell lung cancer with progression of paraneoplastic sensory neuropathy. Lung Cancer 2007; 58: 291-295 [PMID: 17574297 DOI: 10.1016/j.lungcan.2007.05.005]
101. Mawhinney E, Gray OM, McVerry F, McDonnell GV. Paraneoplastic sensorimotor neuropathy associated with regression of small cell lung carcinoma. BMJ Case Rep 2010; 2010: [PMID: 22802230 DOI: 10.1136/bcr.01.2009.1486]
102. Gill S, Murray N, Dalmau J, Thiessen B. Paraneoplastic sensory neuronopathy and spontaneous regression of small cell lung cancer. Can J Neurol Sci 2003; 30: 269-271 [PMID: 12945955]
103. Roberts WK, Deluca IJ, Thomas A, Fak J, Williams T, Buckley N, Dousmanis AG, Posner JB, Darnell RB. Patients with lung cancer and paraneoplastic Hu syndrome harbor HuD-specific type 2 CD8+ T cells. J Clin Invest 2009; 119: 2042-2051 [PMID: 19509467 DOI: 10.1172/JCI36131]
104. de Graaf M, de Beukelaar J, Bergsma J, Kraan J, van den Bent M, Klimek M, van Norden Y, Kusuma A, Smitt PS, Gratama JW. B and T cell imbalances in CSF of patients with Hu-Antibody associated PNS. J Neuroimmunol 2008; 195: 164-170 [PMID: 18358542 DOI: 10.1016/j.jneuroim.2008.01.007]
105. Rousseau A, Benyahia B, Dalmau J, Connan F, Guillet JG, Delattre JY, Choppin J. T cell response to Hu-D peptides in patients with anti-Hu syndrome. J Neurooncol 2005; 71: 231-236 [PMID: 15735910 DOI: 10.1007/s11060-004-1723-1]
106. Suzuki M, Kimura H, Tachibana I, Fujimura H, Nakatsuji Y, Sugai F, Naba I, Nakamori M, Morishita H, Arai T, Osaki T, Hayashi S. Improvement of anti-Hu-Associated paraneoplastic sensory neuropathy after chemoradiotherapy in a small cell lung cancer patient. Intern Med 2001; 40: 1140-1143 [PMID: 11757772 DOI: 10.2169/internalmedicine.40.1140]
107. Gultekin SH, Rosenfeld MR, Voltz R, Eichen J, Posner JB, Dalmau J. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain 2000; 123 ( Pt 7): 1481-1494 [PMID: 10869059 DOI: 10.1093/brain/123.7.1481]
108. Alamowitch S, Graus F, Uchuya M, Reñé R, Bescansa E, Delattre JY. Limbic encephalitis and small cell lung cancer. Clinical and immunological features. Brain 1997; 120 ( Pt 6): 923-928 [PMID: 9217677 DOI: 10.1093/brain/120.6.923]
109. Vincent A, Buckley C, Schott JM, Baker I, Dewar BK, Detert N, Clover L, Parkinson A, Bien CG, Omer S, Lang B, Rossor MN, Palace J. Potassium channel antibody-Associated encephalopathy: A potentially immunotherapy-responsive form of limbic encephalitis. Brain 2004; 127: 701-712 [PMID: 14960497]
110. Pozo-Rosich P, Clover L, Saiz A, Vincent A, Graus F. Voltage-gated potassium channel antibodies in limbic encephalitis. Ann Neurol 2003; 54: 530-533 [PMID: 14520669]
111. Lawn ND, Westmoreland BF, Kiely MJ, Lennon VA, Vernino S. Clinical, magnetic resonance imaging, and electroencephalographic findings in paraneoplastic limbic encephalitis. Mayo Clin Proc 2003; 78: 1363-1368 [PMID: 14601695]
112. Ryu JY, Lee SH, Lee EJ, Min KH, Hur GY, Lee SY, Kim JH, Lee SY, Shin C, Shim JJ, In KH, Kang KH, Yoo SH. A case of paraneoplastic limbic encephalitis associated with small cell lung cancer. Tuberc Respir Dis (Seoul) 2012; 73: 273-277 [PMID: 23236319 DOI: 10.4046/trd.2012.73.5.273]
113. Lalani N, Haq R. Prognostic effect of early treatment of paraneoplastic limbic encephalitis in a patient with smallcell lung cancer. Curr Oncol 2012; 19: e353-e357 [PMID: 23144583 DOI: 10.3747/co.19.1007]
114. Messori A, Lanza C, Serio A, Salvolini U. Resolution of limbic encephalitis with detection and treatment of lung cancer: clinical-radiological correlation. Eur J Radiol 2003; 45: 78-80 [PMID: 12499067]
115. Shamsili S, Grefkens J, de Leeuw B, van den Bent M, Hooijkaas H, van der Holt B, Vecht C, Sillevis Smitt P. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: Analysis of 50 patients. Brain 2003; 126: 1409-1418 [PMID: 12764061 DOI: 10.1093/brain/awg133]
116. Sabater L, Höftberger R, Boronat A, Saiz A, Dalmau J, Graus F. Antibody repertoire in paraneoplastic cerebellar degeneration and small cell lung cancer. PLoS One 2013; 8: e60438 [PMID: 23536908 DOI: 10.1371/journal.pone.0060438]
117. Sabater L, Titulaer M, Saiz A, Verschuuren J, Göre AO, Graus F. SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome. Neurology 2008; 70: 924-928 [PMID: 18032743]
118. Mancuso M, Orsucci D, Bacci A, Caldarazzo Ienco E, Siciliano G. Anti-Ri-Associated paraneoplastic cerebellar degeneration. Report of a case and revision of the literature. Arch Ital Biol 2011; 149: 318-322 [PMID: 22028093 DOI: 10.4449/aib. v149i3.1232]
119. Bruylant K, Crols R, Humbel RL, Appel B, De Deyn PP. Probably anti-Tr associated paraneoplastic cerebellar degeneration as initial presentation of a squamous cell carcinoma of the lung. Clin Neurol Neurosurg 2006; 108: 415-417 [PMID: 16644410]
120. Konishi J, Yamazaki K, Chikai K, Nagashima K, Sakai K, Kinoshita I, Dosaka-Akita H, Nishimura M. Paraneoplastic cerebellar degeneration (PCD) associated with squamous cell carcinoma of the lung. Intern Med 2004; 43: 602-606 [PMID: 15335190]
121. Sabater L, Bataller L, Carpentier AF, Aguirre-Cruz ML, Saiz A, Benyahia B, Dalmau J, Graus F. Protein kinase Cgamma autoimmunity in paraneoplastic cerebellar degeneration and non-small-cell lung cancer. J Neurol Neurosurg Psychiatry 2006; 77: 1359-1362 [PMID: 16801349]
122. Mason WP, Graus F, Lang B, Honnorat J, Delattre JY, Valldeoriola F, Antoine JC, Rosenblum MK, Rosenfeld MR, Newsom-Davis J, Posner JB, Dalmau J. Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome. Brain 1997; 120 ( Pt 8): 1279-1300 [PMID: 9278623]
123. Martín-García E, Mannara F, Gutiérrez-Cuesta J, Sabater L, Dalmau J, Maldonado R, Graus F. Intrathecal injection of P/Q type voltage-gated calcium channel antibodies from paraneoplastic cerebellar degeneration cause ataxia in mice. J Neuroimmunol 2013; 261: 53-59 [PMID: 23726906 DOI: 10.1016/j.jneuroim.2013.05.003]
124. Sabater L, Bataller L, Suárez-Calvet M, Saiz A, Dalmau J, Graus F. ZIC antibodies in paraneoplastic cerebellar degeneration and small cell lung cancer. J Neuroimmunol 2008; 201-202: 163-165 [PMID: 18639938 DOI: 10.1016/j.jneuroim.2008.01.018]
125. Ogawa E, Sakakibara R, Kawashima K, Yoshida T, Kishi M, Tateno F, Kataoka M, Kawashima T, Yamamoto M. VGCC antibody-positive paraneoplastic cerebellar degeneration presenting with positioning vertigo. Neurol Sci 2011; 32: 1209-1212 [PMID: 21678073 DOI: 10.1007/s10072-011-0648-7]
126. Grisold W, Drlicek M, Liszka-Setinek U, Wondrusch E. Anti-Tumour therapy in paraneoplastic neurological disease. Clin Neurol Neurosurg 1995; 97: 106-111 [PMID: 7788965]
127. Bhatia R, Prabhakar S, Lal V, Khurana D, Das CP. Acute onset paraneoplastic cerebellar degeneration in a patient with small cell lung cancer. Neurol India 2003; 51: 244-245 [PMID: 14571014]
128. Keogh M, Sedehizadeh S, Maddison P. Treatment for Lambert-Eaton myasthenic syndrome. Cochrane Database Syst Rev 2011; : CD003279 [PMID: 21328260 DOI: 10.1002/14651858. CD003279.pub3]
129. Titulaer MJ, Maddison P, Sont JK, Wirtz PW, Hilton-Jones D, Klooster R, Willcox N, Potman M, Sillevis Smitt PA, Kuks JB, Roep BO, Vincent A, van der Maarel SM, van Dijk JG, Lang B, Verschuuren JJ. Clinical Dutch-English Lambert-Eaton Myasthenic syndrome (LEMS) tumor association prediction score accurately predicts small-cell lung cancer in the LEMS. J Clin Oncol 2011; 29: 902-908 [PMID: 21245427 DOI: 10.1200/JCO.2010.32.0440]
130. ONeill JH, Murray NM, Newsom-Davis J. The Lambert-Eaton myasthenic syndrome. A review of 50 cases. Brain 1988; 111 ( Pt 3): 577-596 [PMID: 2838124]
131. Nair SG, Kumar BS, Rajan B. Poorly differentiated carcinoma of the lung presenting with Lambert-Eaton myasthenic syndrome. Am J Clin Oncol 2000; 23: 58-59 [PMID: 10683079]
132. Titulaer MJ, Wirtz PW, Willems LN, van Kralingen KW, Smitt PA, Verschuuren JJ. Screening for small-cell lung cancer: A follow-up study of patients with Lambert-Eaton myasthenic syndrome. J Clin Oncol 2008; 26: 4276-4281 [PMID: 18779614 DOI: 10.1200/JCO.2008.17.5133]
133. Titulaer MJ, Lang B, Verschuuren JJ. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol 2011; 10: 1098-1107 [PMID: 22094130 DOI: 10.1016/S1474-4422(11)70245-9]
134. Titulaer MJ, Wirtz PW, Kuks JB, Schelhaas HJ, van der Kooi AJ, Faber CG, van der Pol WL, de Visser M, Sillevis Smitt PA, Verschuuren JJ. The Lambert-Eaton myasthenic syndrome 1988-2008: A clinical picture in 97 patients. J Neuroimmunol 2008; 201-202: 153-158 [PMID: 18644631 DOI: 10.1016/j.jneuroim.2008.05.025]
135. Pourmand R. Lambert-eaton myasthenic syndrome. Front Neurol Neurosci 2009; 26: 120-125 [PMID: 19349709 DOI: 10.1159/000212373]
136. Lorenzoni PJ, Scola RH, Kay CS, Parolin SF, Werneck LC. Non-paraneoplastic Lambert-Eaton myasthenic syndrome: A brief review of 10 cases. Arq Neuropsiquiatr 2010; 68: 849-854 [PMID: 21243240]
137. Oh SJ, Kurokawa K, Claussen GC, Ryan HF. Electrophysiological diagnostic criteria of Lambert-Eaton myasthenic syndrome. Muscle Nerve 2005; 32: 515-520 [PMID: 16003742]
138. Tim RW, Massey JM, Sanders DB. Lambert-Eaton myasthenic syndrome (LEMS). Clinical and electrodiagnostic features and response to therapy in 59 patients. Ann N Y Acad Sci 1998; 841: 823-826 [PMID: 9668336]
139. Hatanaka Y, Oh SJ. Ten-second exercise is superior to 30-second exercise for post-exercise facilitation in diagnosing Lambert-Eaton myasthenic syndrome. Muscle Nerve 2008; 37: 572-575 [PMID: 18288711 DOI: 10.1002/mus.20979]
140. Martin-Moutot N, De Haro L, Seagar M. Distinct evolution of calcium channel antibody types in Lambert-Eaton myasthenic syndrome. J Neuroimmunol 2008; 197: 47-53 [PMID: 18474401 DOI: 10.1016/j.jneuroim.2008.04.001]
141. Titulaer MJ, Klooster R, Potman M, Sabater L, Graus F, Hegeman IM, Thijssen PE, Wirtz PW, Twijnstra A, Smitt PA, van der Maarel SM, Verschuuren JJ. SOX antibodies in small-cell lung cancer and Lambert-Eaton myasthenic syndrome: frequency and relation with survival. J Clin Oncol 2009; 27: 4260-4267 [PMID: 19667272 DOI: 10.1200/JCO.2008.20.6169]
142. Maddison P, Lang B, Mills K, Newsom-Davis J. Long term outcome in Lambert-Eaton myasthenic syndrome without lung cancer. J Neurol Neurosurg Psychiatry 2001; 70: 212-217 [PMID: 11160470]
143. Sanders DB, Juel VC. The Lambert-Eaton myasthenic syndrome. Handb Clin Neurol 2008; 91: 273-283 [PMID: 18631847 DOI: 10.1016/S0072-9752(07)01509-6]
144. Molgó J, Lundh H, Thesleff S. Potency of 3, 4-diaminopyridine and 4-Aminopyridine on mammalian neuromuscular transmission and the effect of pH changes. Eur J Pharmacol 1980; 61: 25-34 [PMID: 6101553]
145. Wu ZZ, Li DP, Chen SR, Pan HL. Aminopyridines potentiate synaptic and neuromuscular transmission by targeting the voltage-Activated calcium channel beta subunit. J Biol Chem 2009; 284: 36453-36461 [PMID: 19850918 DOI: 10.1074/jbc.M109.075523]
146. McEvoy KM, Windebank AJ, Daube JR, Low PA. 3, 4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome. N Engl J Med 1989; 321: 1567-1571 [PMID: 2555713]
147. Oh SJ, Claussen GG, Hatanaka Y, Morgan MB. 3, 4-Diaminopyridine is more effective than placebo in a randomized, double-blind, cross-over drug study in LEMS. Muscle Nerve 2009; 40: 795-800 [PMID: 19722254 DOI: 10.1002/mus.21422]
148. Sanders DB, Massey JM, Sanders LL, Edwards LJ. A randomized trial of 3, 4-diaminopyridine in Lambert-Eaton myasthenic syndrome. Neurology 2000; 54: 603-607 [PMID: 10680790]
149. Wirtz PW, Verschuuren JJ, van Dijk JG, de Kam ML, Schoemaker RC, van Hasselt JG, Titulaer MJ, Tjaden UR, den Hartigh J, van Gerven JM. Efficacy of 3, 4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: A randomized, double-blind, placebocontrolled, crossover study. Clin Pharmacol Ther 2009; 86: 44-48 [PMID: 19357643 DOI: 10.1038/clpt.2009.35]
150. Lindquist S, Stangel M. Update on treatment options for Lambert-Eaton myasthenic syndrome: focus on use of amifampridine. Neuropsychiatr Dis Treat 2011; 7: 341-349 [PMID: 21822385 DOI: 10.2147/NDT.S10464]
151. Bain PG, Motomura M, Newsom-Davis J, Misbah SA, Chapel HM, Lee ML, Vincent A, Lang B. Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Neurology 1996; 47: 678-683 [PMID: 8797464 DOI: 10.1212/WNL.47.3.678]
152. Ahmed MN, Carpenter S. Autonomic neuropathy and carcinoma of the lung. Can Med Assoc J 1975; 113: 410-412 [PMID: 168952]
153. Sørhaug S, Steinshamn SL, Waldum HL. Octreotide treatment for paraneoplastic intestinal pseudo-obstruction complicating SCLC. Lung Cancer 2005; 48: 137-140 [PMID: 15777981 DOI: 10.1016/j.lungcan.2004.09.008]
154. Donthireddy KR, Ailawadhi S, Nasser E, Schiff MD, Nwogu CE, Nava HR, Javle MM. Malignant gastroparesis: pathogenesis and management of an underrecognized disorder. J Support Oncol 2007; 5: 355-363 [PMID: 17944143]
155. Lucchinetti CF, Kimmel DW, Lennon VA. Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies. Neurology 1998; 50: 652-657 [PMID: 9521251 DOI: 10.1212/WNL.50.3.652]
156. Lee HR, Lennon VA, Camilleri M, Prather CM. Paraneoplastic gastrointestinal motor dysfunction: clinical and laboratory characteristics. Am J Gastroenterol 2001; 96: 373-379 [PMID: 11232678 DOI: 10.1111/j.1572-0241.2001.03454.x]
157. Nguyen-Tat M, Pohl J, Gönter E, Manner H, Plum N, Pech O, Ell C. Severe paraneoplastic gastroparesis associated with anti-Hu antibodies preceding the manifestation of smallcell lung cancer. Z Gastroenterol 2008; 46: 274-278 [PMID: 18322883 DOI: 10.1055/s-2007-963429]
158. Pardi DS, Miller SM, Miller DL, Burgart LJ, Szurszewski JH, Lennon VA, Farrugia G. Paraneoplastic dysmotility: loss of interstitial cells of Cajal. Am J Gastroenterol 2002; 97: 1828-1833 [PMID: 12135044]
159. Jun S, Dimyan M, Jones KD, Ladabaum U. Obstipation as a paraneoplastic presentation of small cell lung cancer: case report and literature review. Neurogastroenterol Motil 2005; 17: 16-22 [PMID: 15670259]
160. De Giorgio R, Guerrini S, Barbara G, Stanghellini V, De Ponti F, Corinaldesi R, Moses PL, Sharkey KA, Mawe GM. Inflammatory neuropathies of the enteric nervous system. Gastroenterology 2004; 126: 1872-1883 [PMID: 15188182]
161. Vedeler CA, Antoine JC, Giometto B, Graus F, Grisold W, Hart IK, Honnorat J, Sillevis Smitt PA, Verschuuren JJ, Voltz R. Management of paraneoplastic neurological syndromes: report of an EFNS Task Force. Eur J Neurol 2006; 13: 682-690 [PMID: 16834698]
162. Zahr ZA, Baer AN. Malignancy in myositis. Curr Rheumatol Rep 2011; 13: 208-215 [PMID: 21336621 DOI: 10.1007/s11926-011-0169-7]
163. Zhang W, Jiang SP, Huang L. Dermatomyositis and malignancy: A retrospective study of 115 cases. Eur Rev Med Pharmacol Sci 2009; 13: 77-80 [PMID: 19499841]
164. Prohic A, Kasumagic-Halilovic E, Simic D, Selmanagic A. Clinical and biological factors predictive of malignancy in dermatomyositis. J Eur Acad Dermatol Venereol 2009; 23: 591-592 [PMID: 18752541 DOI: 10.1111/j.1468-3083.2008.02971.x]
165. Fardet L, Dupuy A, Gain M, Kettaneh A, Chérin P, Bachelez H, Dubertret L, Lebbe C, Morel P, Rybojad M. Factors associated with underlying malignancy in a retrospective cohort of 121 patients with dermatomyositis. Medicine (Baltimore) 2009; 88: 91-97 [PMID: 19282699 DOI: 10.1097/MD.0b013e31819da352]
166. Na SJ, Kim SM, Sunwoo IN, Choi YC. Clinical characteristics and outcomes of juvenile and adult dermatomyositis. J Korean Med Sci 2009; 24: 715-721 [PMID: 19654958 DOI: 10.3346/jkms.2009.24.4.715]
167. Hill CL, Zhang Y, Sigurgeirsson B, Pukkala E, Mellemkjaer L, Airio A, Evans SR, Felson DT. Frequency of specific cancer types in dermatomyositis and polymyositis: A population-based study. Lancet 2001; 357: 96-100 [PMID: 11197446]
168. Huang YL, Chen YJ, Lin MW, Wu CY, Liu PC, Chen TJ, Chen YC, Jih JS, Chen CC, Lee DD, Chang YT, Wang WJ, Liu HN. Malignancies associated with dermatomyositis and polymyositis in Taiwan: A nationwide population-based study. Br J Dermatol 2009; 161: 854-860 [PMID: 19558555 DOI: 10.1111/j.1365-2133.2009.09274.x]
169. Hunger RE, Dörr C, Brand CU. Cutaneous leukocytoclastic vasculitis in dermatomyositis suggests malignancy. Dermatology 2001; 202: 123-126 [PMID: 11306833]
170. Zangrilli A, Papoutsaki M, Bianchi L, Teoli M, Chimenti S. Bullous dermatomyositis: A marker of poor prognosis and aggressive internal malignancy? Acta Derm Venereol 2008; 88: 393-394 [PMID: 18709313 DOI: 10.2340/00015555-0455]
171. Acciavatti A, Avolio T, Rappuoli S, Foderi L, Soldati V, Franchi M, Volpi N, Nuti R. Paraneoplastic necrotizing myopathy associated with adenocarcinoma of the lung-A rare entity with atypical onset: A case report. J Med Case Rep 2013; 7: 112 [PMID: 23618006 DOI: 10.1186/1752-1947-7-112]
172. Chinoy H, Fertig N, Oddis CV, Ollier WE, Cooper RG. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-Associated myositis. Ann Rheum Dis 2007; 66: 1345-1349 [PMID: 17392346]
173. Fujita J, Tokuda M, Bandoh S, Yang Y, Fukunaga Y, Hojo S, Ueda Y, Dobashi N, Dohmoto K, Ishida T, Takahara J. Primary lung cancer associated with polymyositis/dermatomyositis, with a review of the literature. Rheumatol Int 2001; 20: 81-84 [PMID: 11269538]
174. Zang YS, Xiu QY, Fang Z, Li B, Xia TB. Case report: dramatic recovery of lung adenocarcinoma-Associated dermatomyositis with targeted lung cancer therapy alone. Oncologist 2008; 13: 79-81 [PMID: 18245014 DOI: 10.1634/theoncologist. 2007-0172]
175. Milanez FM, Pereira CA, Trindade PH, Milinavicius R, Coletta EN. Lung adenocarcinoma, dermatomyositis, and Lambert-Eaton myasthenic syndrome: A rare combination. J Bras Pneumol 2008; 34: 333-336 [PMID: 18545831]
176. Nicotera SP, Miller EC, Nghiem FT, DeCamp MM, Michaud G, Kent MS. Bronchopulmonary carcinoid tumor presenting with polymyositis. Ann Thorac Surg 2010; 89: 1276-1278 [PMID: 20338355 DOI: 10.1016/j.athoracsur.2009.08.054]
177. Przybylski G, Jarzemska A, Czerniak J, Siemiatkowska K, Gadzińska A, Cies̈liński K. A case report of a patient with dermatomyositis as a prodromal sign of lung cancer. Pol Arch Med Wewn 2008; 118: 143-147 [PMID: 18476461]
178. András C, Ponyi A, Constantin T, Csiki Z, Szekanecz E, Szodoray P, Dankó K. Dermatomyositis and polymyositis associated with malignancy: A 21-year retrospective study. J Rheumatol 2008; 35: 438-444 [PMID: 18203322]
179. Bonnetblanc JM, Bernard P, Fayol J. Dermatomyositis and malignancy. A multicenter cooperative study. Dermatologica 1990; 180: 212-216 [PMID: 2192925]
180. Mori H, Habe K, Hakamada A, Isoda K, Mizutani H. Relapse of dermatomyositis after 10 years in remission following curative surgical treatment of lung cancer. J Dermatol 2005; 32: 290-294 [PMID: 15863853]
181. Bohan A, Peter JB, Bowman RL, Pearson CM. Computerassisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine (Baltimore) 1977; 56: 255-286 [PMID: 327194]
182. Hidano A, Torikai S, Uemura T, Shimizu S. Malignancy and interstitial pneumonitis as fatal complications in dermatomyositis. J Dermatol 1992; 19: 153-160 [PMID: 1640021]
183. Leow YH, Goh CL. Malignancy in adult dermatomyositis. Int J Dermatol 1997; 36: 904-907 [PMID: 9466195]
184. Casciola-Rosen L, Nagaraju K, Plotz P, Wang K, Levine S, Gabrielson E, Corse A, Rosen A. Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med 2005; 201: 591-601 [PMID: 15728237]
185. Ohara S, Iijima N, Hayashida K, Oide T, Katai S. Autopsy case of opsoclonus-myoclonus-Ataxia and cerebellar cognitive affective syndrome associated with small cell carcinoma of the lung. Mov Disord 2007; 22: 1320-1324 [PMID: 17534981]
186. Bataller L, Graus F, Saiz A, Vilchez JJ. Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus. Brain 2001; 124: 437-443 [PMID: 11157570]
187. Digre KB. Opsoclonus in adults. Report of three cases and review of the literature. Arch Neurol 1986; 43: 1165-1175 [PMID: 3535750]
188. Vandervest KM, Schwarz MI. A 76-year-old woman with acute CNS symptoms and pulmonary nodules. Chest 2009; 136: 1686-1689 [PMID: 19995771 DOI: 10.1378/chest.09-1180]
189. Baets J, Pals P, Bergmans B, Foncke E, Smets K, Hauman H, Vanderwegen L, Cras P. Opsoclonus-myoclonus syndrome: A clinicopathological confrontation. Acta Neurol Belg 2006; 106: 142-146 [PMID: 17091618]
190. Musunuru K, Kesari S. Paraneoplastic opsoclonus-myoclonus ataxia associated with non-small-cell lung carcinoma. J Neurooncol 2008; 90: 213-216 [PMID: 18618225 DOI: 10.1007/s11060-008-9650-1]
191. Hiasa Y, Kunishige M, Mitsui T, Kondo S, Kuriwaka R, Shigekiyo S, Kanematsu T, Satake N, Bando Y, Kondo A, Endo I, Oshima Y, Matsumoto T. Complicated paraneoplastic neurological syndromes: A report of two patients with small cell or non-small cell lung cancer. Clin Neurol Neurosurg 2003; 106: 47-49 [PMID: 14643918]
192. Erlich R, Morrison C, Kim B, Gilbert MR, Alrajab S. ANNA-2: An antibody associated with paraneoplastic opsoclonus in a patient with large-cell carcinoma of the lung with neuroendocrine features-correlation of clinical improvement with tumor response. Cancer Invest 2004; 22: 257-261 [PMID: 15199608]
193. Blaes F, Jauss M, Kraus J, Oschmann P, Krasenbrink I, Kaps M, Teegen B. Adult paraneoplastic opsoclonus-myoclonus syndrome associated with antimitochondrial autoantibodies. J Neurol Neurosurg Psychiatry 2003; 74: 1595-1596 [PMID: 14617731]
194. de Beukelaar JW, Sillevis Smitt PA. Managing paraneoplastic neurological disorders. Oncologist 2006; 11: 292-305 [PMID: 16549814]
195. Hassan KA, Kalemkerian GP, Trobe JD. Long-Term survival in paraneoplastic opsoclonus-myoclonus syndrome associated with small cell lung cancer. J Neuroophthalmol 2008; 28: 27-30 [PMID: 18347455 DOI: 10.1097/WNO.0b013e318167550a]
196. Chalk CH, Windebank AJ, Kimmel DW, McManis PG. The distinctive clinical features of paraneoplastic sensory neuronopathy. Can J Neurol Sci 1992; 19: 346-351 [PMID: 1393844]
197. Graus F, Keime-Guibert F, Reñe R, Benyahia B, Ribalta T, Ascaso C, Escaramis G, Delattre JY. Anti-Hu-Associated paraneoplastic encephalomyelitis: Analysis of 200 patients. Brain 2001; 124: 1138-1148 [PMID: 11353730]
198. Sillevis Smitt P, Grefkens J, de Leeuw B, van den Bent M, van Putten W, Hooijkaas H, Vecht C. Survival and outcome in 73 anti-Hu positive patients with paraneoplastic encephalomyelitis/sensory neuronopathy. J Neurol 2002; 249: 745-753 [PMID: 12111309]
199. Antoine JC, Camdessanché JP. Peripheral nervous system involvement in patients with cancer. Lancet Neurol 2007; 6: 75-86 [PMID: 17166804]
200. Dhand UK, Sahaya K, Singh NN. Paraneoplastic sensory neuropathy and ganglionic acetylcholine receptor antibody. Muscle Nerve 2011; 44: 458-459 [PMID: 21996812 DOI: 10.1002/mus.22147]
201. Keime-Guibert F, Graus F, Broët P, Reñé R, Molinuevo JL, Ascaso C, Delattre JY. Clinical outcome of patients with anti-Hu-Associated encephalomyelitis after treatment of the tumor. Neurology 1999; 53: 1719-1723 [PMID: 10563618]
202. Uchuya M, Graus F, Vega F, Reñé R, Delattre JY. Intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with antineuronal autoantibodies. J Neurol Neurosurg Psychiatry 1996; 60: 388-392 [PMID: 8774401]
203. Bazex A, Griffiths A. Acrokeratosis paraneoplastica-A new cutaneous marker of malignancy. Br J Dermatol 1980; 103: 301-306 [PMID: 7000146]
204. Bolognia JL. Bazex syndrome: Acrokeratosis paraneoplastica. Semin Dermatol 1995; 14: 84-89 [PMID: 7640201]
205. Strobel ES, Bouveret C, Kohl PK. Acrokeratosis paraneo-plastica of Bazex as an indicator for underlying squamous cell carcinoma of the lung. J Cancer Res Clin Oncol 2006; 132: 376-378 [PMID: 16435144]
206. Valdivielso M, Longo I, Suárez R, Huerta M, Lázaro P. Acrokeratosis paraneoplastica: Bazex syndrome. J Eur Acad Dermatol Venereol 2005; 19: 340-344 [PMID: 15857461]
207. Crucitti A, Feliciani C, Grossi U, La Greca A, Porziella V, Giustacchini P, Congedo MT, Fronterré P, Granone PM. Paraneoplastic acrokeratosis (bazex syndrome) in lung cancer. J Clin Oncol 2009; 27: e266-e268 [PMID: 19826120 DOI: 10.1200/JCO.2009.22.6852]
208. Zarzour JG, Singh S, Andea A, Cafardi JA. Acrokeratosis paraneoplastica (Bazex syndrome): report of a case associated with small cell lung carcinoma and review of the literature. J Radiol Case Rep 2011; 5: 1-6 [PMID: 22470801 DOI: 10.3941/jrcr.v5i7.663]
209. Karabulut AA, Sahin S, Sahin M, Ekşioglu M, Ustön H. Paraneoplastic acrokeratosis of Bazex (Bazex's syndrome): report of a female case associated with cholangiocarcinoma and review of the published work. J Dermatol 2006; 33: 850-854 [PMID: 17169088]
210. Stone SP, Buescher LS. Life-Threatening paraneoplastic cutaneous syndromes. Clin Dermatol 2005; 23: 301-306 [PMID: 15896545]
211. Hsu YS, Lien GS, Lai HH, Cheng YS, Hu CH, Hsieh MC, Fang CL, Pan S. Acrokeratosis paraneoplastica (Bazex syndrome) with adenocarcinoma of the colon: report of a case and review of the literature. J Gastroenterol 2000; 35: 460-464 [PMID: 10864355]
212. Iihara K, Shiozaki H, Oku K, Tahara H, Doki Y, Oka H, Kadowaki T, Iwazawa T, Inoue M, Mori T. Growth-regulatory mechanism of two human esophageal-cancer cell lines in protein-free conditions. Int J Cancer 1993; 55: 364-370 [PMID: 8375919]
213. Spellman JE, Kulesz-Martin MF, Blumenson LE, Beckett MA, Weichselbaum RR. Clonal interactions in a human squamous cell carcinoma. J Surg Res 1995; 58: 165-174 [PMID: 7861768]
214. Krawczyk M, Mykala-Cies̈ la J, Kolodziej-Jaskul a A. Acanthosis nigricans as a paraneoplastic syndrome. Case reports and review of literature. Pol Arch Med Wewn 2009; 119: 180-183 [PMID: 19514649]
215. Yeh JS, Munn SE, Plunkett TA, Harper PG, Hopster DJ, du Vivier AW. Coexistence of acanthosis nigricans and the sign of Leser-Trélat in a patient with gastric adenocarcinoma: A case report and literature review. J Am Acad Dermatol 2000; 42: 357-362 [PMID: 10640933]
216. Mukherjee S, Pandit S, Deb J, Dattachaudhuri A, Bhuniya S, Bhanja P. A case of squamous cell carcinoma of lung presenting with paraneoplastic type of acanthosis nigricans. Lung India 2011; 28: 62-64 [PMID: 21654990 DOI: 10.4103/0970-2113.76305]
217. Heaphy MR, Millns JL, Schroeter AL. The sign of Leser-Trélat in a case of adenocarcinoma of the lung. J Am Acad Dermatol 2000; 43: 386-390 [PMID: 10901731]
218. Kannenberg SM, Koegelenberg CF, Jordaan HF, Bolliger CT. A patient with leonine facies and occult lung disease. Respiration 2010; 79: 250-254 [PMID: 19864869 DOI: 10.1159/000247186]
219. Pentenero M, Carrozzo M, Pagano M, Gandolfo S. Oral acanthosis nigricans, tripe palms and sign of leser-Trélat in a patient with gastric adenocarcinoma. Int J Dermatol 2004; 43: 530-532 [PMID: 15230897]
220. Khaled A, Abdallah MB, Tekaya R, Kharfi M, Belhadj Yahia C, Zouari R, Kamoun MR. Tripe palms with oligoarthritis, two rare paraneoplastic syndromes heralding a small cell lung cancer. J Eur Acad Dermatol Venereol 2009; 23: 579-580 [PMID: 19415809 DOI: 10.1111/j.1468-3083.2008.02962.x]
221. Cohen PR, Grossman ME, Silvers DN, Kurzrock R. Tripe palms and cancer. Clin Dermatol 1993; 11: 165-173 [PMID: 8339193]
222. Dasanu CA, Alexandrescu DT. Bilateral Leser-Trélat sign mirroring lung adenocarcinoma with early metastases to the contralateral lung. South Med J 2009; 102: 216-218 [PMID: 19209445]
223. Cruz PD, Hud JA. Excess insulin binding to insulin-like growth factor receptors: proposed mechanism for acanthosis nigricans. J Invest Dermatol 1992; 98: 82S-85S [PMID: 1316928]
224. De La Torre-Lugo EM, Sánchez JL. Erythema gyratum repens. J Am Acad Dermatol 2011; 64: e89-e90 [PMID: 21496697 DOI: 10.1016/j.jaad.2010.10.006]
225. Boyd AS, Neldner KH, Menter A. Erythema gyratum repens: A paraneoplastic eruption. J Am Acad Dermatol 1992; 26: 757-762 [PMID: 1583177]
226. Olsen TG, Milroy SK, Jones-Olsen S. Erythema gyratum repens with associated squamous cell carcinoma of the lung. Cutis 1984; 34: 351-353, 355 [PMID: 6488889]
227. Serrão V, Martins A, Ponte P, Baptista J, Apetato M, Feio AB. Erythema gyratum repens as the initial manifestation of lung cancer. Eur J Dermatol 2008; 18: 197-198 [PMID: 18424390 DOI: 10.1684/ejd.2008.0368]
228. Möller CS, Lorenz MT, Tilgen W, Rass K. Primary manifestation of erythema gyratum repens as a transient erythroderma in a patient with bronchial carcinoma. Int J Dermatol 2010; 49: 676-678 [PMID: 20618474 DOI: 10.1111/j.1365-4632.2009.04387.x]
229. Odeh M, Misselevich I, Oliven A. Squamous cell carcinoma of the lung presenting with cutaneous leukocytoclastic vasculitis: A case report. Angiology 2001; 52: 641-644 [PMID: 11570664]
230. Fain O, Hamidou M, Cacoub P, Godeau B, Wechsler B, Pariès J, Stirnemann J, Morin AS, Gatfosse M, Hanslik T, Belmatoug N, Blétry O, Cevallos R, Delevaux I, Fisher E, Hayem G, Kaplan G, Le Hello C, Mouthon L, Larroche C, Lemaire V, Piette AM, Piette JC, Ponge T, Puechal X, Rossert J, Sarrot-Reynauld F, Sicard D, Ziza JM, Kahn MF, Guillevin L. Vasculitides associated with malignancies: Analysis of sixty patients. Arthritis Rheum 2007; 57: 1473-1480 [PMID: 18050165]
231. Kurzrock R, Cohen PR, Markowitz A. Clinical manifestations of vasculitis in patients with solid tumors. A case report and review of the literature. Arch Intern Med 1994; 154: 334-340 [PMID: 8297201]
232. Solans-Laqué R, Bosch-Gil JA, Pérez-Bocanegra C, Selva-O Callaghan A, Simeón-Aznar CP, Vilardell-Tarres M. Paraneoplastic vasculitis in patients with solid tumors: report of 15cases. J Rheumatol 2008; 35: 294-304 [PMID: 18085729]
233. Kathula SK, Thomas DE, Anstadt MP, Khan AU. Paraneoplastic cutaneous leukocytoclastic vasculitis and iron deficiency anemia as the presenting features of squamous cell lung carcinoma. J Clin Oncol 2011; 29: e83-e85 [PMID: 21098328 DOI: 10.1200/JCO.2010.31.4708]
234. Carlson JA. The histological assessment of cutaneous vasculitis. Histopathology 2010; 56: 3-23 [PMID: 20055902 DOI: 10.1111/j.1365-2559.2009.03443.x]
235. King MM, Nelson DA. Hypertrophic osteoarthropathy effectively treated with zoledronic acid. Clin Lung Cancer 2008; 9: 179-182 [PMID: 18621629 DOI: 10.3816/CLC.2008.n.027]
236. Martínez-Lavín M, Matucci-Cerinic M, Jajic I, Pineda C. Hypertrophic osteoarthropathy: consensus on its definition, classification, assessment and diagnostic criteria. J Rheumatol 1993; 20: 1386-1387 [PMID: 7901413]
237. Yao Q, Altman RD, Brahn E. Periostitis and hypertrophic pulmonary osteoarthropathy: report of 2 cases and review of the literature. Semin Arthritis Rheum 2009; 38: 458-466 [PMID: 18760449 DOI: 10.1016/j.semarthrit.2008.07.001]
238. Davis MC, Sherry V. Hypertrophic osteoarthropathy as a clinical manifestation of lung cancer. Clin J Oncol Nurs 2011; 15: 561-563 [PMID: 21951743 DOI: 10.1188/11. CJON.561-563]
239. Ito T, Goto K, Yoh K, Niho S, Ohmatsu H, Kubota K, Nagai K, Miyazaki E, Kumamoto T, Nishiwaki Y. Hypertrophic pulmonary osteoarthropathy as a paraneoplastic manifestation of lung cancer. J Thorac Oncol 2010; 5: 976-980 [PMID: 20453688 DOI: 10.1097/JTO.0b013e3181dc1f3c]
240. Makis W, Abikhzer G, Rush C. Hypertrophic pulmonary osteoarthropathy diagnosed by FDG PET-CT in a patient with lung adenocarcinoma. Clin Nucl Med 2009; 34: 625-627 [PMID: 19692831 DOI: 10.1097/RLU.0b013e3181b06c1a]
241. Strobel K, Schaefer NG, Husarik DB, Hany TF, Steinert H. Pulmonary hypertrophic osteoarthropathy in a patient with nonsmall cell lung cancer: Diagnosis with FDG PET/CT. Clin Nucl Med 2006; 31: 624-626 [PMID: 16985370 DOI: 10.1097/01.rlu.0000237961.55906.37]
242. Dickinson CJ, Martin JF. Megakaryocytes and platelet clumps as the cause of finger clubbing. Lancet 1987; 2: 1434-1435 [PMID: 2891996 DOI: 10.1016/S0140-6736(87)91132-9]
243. Atkinson S, Fox SB. Vascular endothelial growth factor (VEGF)-A and platelet-derived growth factor (PDGF) play a central role in the pathogenesis of digital clubbing. J Pathol 2004; 203: 721-728 [PMID: 15141388 DOI: 10.1002/path.1565]
244. Silveira LH, Martínez-Lavín M, Pineda C, Fonseca MC, Navarro C, Nava A. Vascular endothelial growth factor and hypertrophic osteoarthropathy. Clin Exp Rheumatol 2000; 18: 57-62 [PMID: 10728444]
245. Olán F, Portela M, Navarro C, Gaxiola M, Silveira LH, Ruiz V, Martínez-Lavín M. Circulating vascular endothelial growth factor concentrations in a case of pulmonary hypertrophic osteoarthropathy. Correlation with disease activity. J Rheumatol 2004; 31: 614-616 [PMID: 14994415]
246. Silveri F, De Angelis R, Argentati F, Brecciaroli D, Muti S, Cervini C. Hypertrophic osteoarthropathy: endothelium and platelet function. Clin Rheumatol 1996; 15: 435-439 [PMID: 8894355 DOI: 10.1007/BF02229639]
247. Albrecht S, Keller A. Postchemotherapeutic reversibility of hypertrophic osteoarthropathy in a patient with bronchogenic adenocarcinoma. Clin Nucl Med 2003; 28: 463-466 [PMID: 12911093 DOI: 10.1097/01.RLU.0000067504.35952.10]
248. Poanta L, Parasca I, Fazakas E, Porojan M, Pais R, Boian L. Paraneoplastic hypertrophic osteoarthropathy: evaluation at25 years after pneumectomy. Pol Arch Med Wewn 2009; 119: 603-606 [PMID: 19776708]
249. Shih WJ. Pulmonary hypertrophic osteoarthropathy and its resolution. Semin Nucl Med 2004; 34: 159-163 [PMID: 15031816 DOI: 10.1053/j.semnuclmed.2004.01.001]
250. Hayashi M, Sekikawa A, Saijo A, Takada W, Yamawaki I, Ohkawa S. Successful treatment of hypertrophic osteoarthropathy by gefitinib in a case with lung adenocarcinoma. Anticancer Res 2005; 25: 2435-2438 [PMID: 16080471]
251. Bernardo SG, Emer JJ, Burnett ME, Gordon M. Hypertrophic osteoarthropathy presenting as unilateral cellulitis with successful treatment using pamidronate disodium. J Clin Aesthet Dermatol 2012; 5: 37-46 [PMID: 23050033]
252. Amital H, Applbaum YH, Vasiliev L, Rubinow A. Hypertrophic pulmonary osteoarthropathy: control of pain and symptoms with pamidronate. Clin Rheumatol 2004; 23: 330-332 [PMID: 15293094 DOI: 10.1007/s10067-004-0941-4]
253. Santini D, Vincenzi B, Avvisati G, Dicuonzo G, Battistoni F, Gavasci M, Salerno A, Denaro V, Tonini G. Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res 2002; 8: 1080-1084 [PMID: 12006522]
254. Angel-Moreno Maroto A, Martínez-Quintana E, Suárez-Castellano L, Pérez-Arellano JL. Painful hypertrophic osteoarthropathy successfully treated with octreotide. The pathogenetic role of vascular endothelial growth factor (VEGF). Rheumatology (Oxford) 2005; 44: 1326-1327 [PMID: 15972353 DOI: 10.1093/rheumatology/keh720]
255. Johnson SA, Spiller PA, Faull CM. Treatment of resistant pain in hypertrophic pulmonary osteoarthropathy with subcutaneous octreotide. Thorax 1997; 52: 298-299 [PMID: 9093354 DOI: 10.1136/thx.52.3.298]
256. Dasgupta P. Somatostatin analogues: multiple roles in cellular proliferation, neoplasia, and angiogenesis. Pharmacol Ther 2004; 102: 61-85 [PMID: 15056499 DOI: 10.1016/j.pharm thera.2004.02.002]
257. Kasuga I, Makino S, Kiyokawa H, Katoh H, Ebihara Y, Ohyashiki K. Tumor-related leukocytosis is linked with poor prognosis in patients with lung carcinoma. Cancer 2001; 92: 2399-2405 [PMID: 11745296 DOI: 10.1002/1097-014 2(20011101)922399: : AID-CNCR1588: 93.0.CO; 2-W]
258. Riesenberg H, Möller F, Görner M. Leukemoid reaction in a patient with adenocarcinoma of the lung: A case report. J Med Case Rep 2012; 6: 211 [PMID: 22812671 DOI: 10.1186/1752-1947-6-211]
259. Maione P, Rossi A, Di Maio M, Gridelli C. Tumor-related leucocytosis and chemotherapy-induced neutropenia: linked or independent prognostic factors for advanced nonsmall cell lung cancer? Lung Cancer 2009; 66: 8-14 [PMID: 19328587 DOI: 10.1016/j.lungcan.2009.02.022]
260. Pandit R, Scholnik A, Wulfekuhler L, Dimitrov N. Nonsmall-cell lung cancer associated with excessive eosinophilia and secretion of interleukin-5 as a paraneoplastic syndrome. Am J Hematol 2007; 82: 234-237 [PMID: 17160990]
261. El-Osta H, El-Haddad P, Nabbout N. Lung carcinoma associated with excessive eosinophilia. J Clin Oncol 2008; 26: 3456-3457 [PMID: 18612162 DOI: 10.1200/JCO.2007.15.8899]
262. Verstraeten AS, De Weerdt A, van Den Eynden G, Van Marck E, Snoeckx A, Jorens PG. Excessive eosinophilia as paraneoplastic syndrome in a patient with non-small-cell lung carcinoma: A case report and review of the literature. Acta Clin Belg 2011; 66: 293-297 [PMID: 21938985]
263. Matsumoto S, Tamai T, Yanagisawa K, Kawamura S, Fujita S. Lung cancer with eosinophilia in the peripheral blood and the pleural fluid. Intern Med 1992; 31: 525-529 [PMID: 1633363 DOI: 10.2169/internalmedicine.31.525]
264. Henry DW, Rosenthal A, McCarty DJ. Adenocarcinoma of the lung associated with eosinophilia and hidebound skin. J Rheumatol 1994; 21: 972-973 [PMID: 8064750]
265. Watanabe M, Ono K, Ozeki Y, Tanaka S, Aida S, Okuno Y. Production of granulocyte-macrophage colony-stimulating factor in a patient with metastatic chest wall large cell carcinoma. Jpn J Clin Oncol 1998; 28: 559-562 [PMID: 9793030 DOI: 10.1093/jjco/28.9.559]
266. Sawyers CL, Golde DW, Quan S, Nimer SD. Production of granulocyte-macrophage colony-stimulating factor in two patients with lung cancer, leukocytosis, and eosinophilia. Cancer 1992; 69: 1342-1346 [PMID: 1540871 DOI: 10.1002/1097-0142(19920315)691342: : AIDCNCR2820690607: 6 3.0.CO; 2-U]
267. Stefanini M, Claustro JC, Motos RA, Bendigo LL. Blood and bone marrow eosinophilia in malignant tumors. Role and nature of blood and tissue eosinophil colony-stimulating factor(s) in two patients. Cancer 1991; 68: 543-548 [PMID: 2065275 DOI: 10.1002/1097-0142(19910801)68543: : AIDCNCR2820680317: 3 3.0.CO; 2-3]
268. Rivoltini L, Viggiano V, Spinazzè S, Santoro A, Colombo MP, Takatsu K, Parmiani G. In vitro anti-Tumor activity of eosinophils from cancer patients treated with subcutaneous administration of interleukin 2. Role of interleukin 5. Int J Cancer 1993; 54: 8-15 [PMID: 8386711 DOI: 10.1002/ijc.2910540103]
269. Aoe K, Hiraki A, Ueoka H, Kiura K, Tabata M, Tanaka M, Tanimoto M. Thrombocytosis as a useful prognostic indicator in patients with lung cancer. Respiration 2004; 71: 170-173 [PMID: 15031573 DOI: 10.1159/000076679]
270. Gislason T, Nu E. Sedimentation rate, leucocytes, platelet count and haemoglobin in bronchial carcinoma: An epidemiological study. Eur J Respir Dis 1985; 66: 141-146 [PMID: 2982631]
271. Pedersen LM, Milman N. Prognostic significance of thrombocytosis in patients with primary lung cancer. Eur Respir J 1996; 9: 1826-1830 [PMID: 8880098 DOI: 10.1183/09031936.9 6.09091826]
272. Blay JY, Favrot M, Rossi JF, Wijdenes J. Role of interleukin-6 in paraneoplastic thrombocytosis. Blood 1993; 82: 2261-2262 [PMID: 8400277]
273. Shikada Y, Yonemitsu Y, Koga T, Onimaru M, Nakano T, Okano S, Sata S, Nakagawa K, Yoshino I, Maehara Y, Sueishi K. Platelet-derived growth factor-AA is an essential and autocrine regulator of vascular endothelial growth factor expression in non-small cell lung carcinomas. Cancer Res 2005; 65: 7241-7248 [PMID: 16103075 DOI: 10.1158/0008-5472. CAN-04-4171]
274. Xu L, Tong R, Cochran DM, Jain RK. Blocking plateletderived growth factor-D/platelet-derived growth factor receptor beta signaling inhibits human renal cell carcinoma progression in an orthotopic mouse model. Cancer Res 2005; 65: 5711-5719 [PMID: 15994946]
275. Bacchetta J, Juillard L, Cochat P, Droz JP. Paraneoplastic glomerular diseases and malignancies. Crit Rev Oncol Hematol 2009; 70: 39-58 [PMID: 18790651 DOI: 10.1016/j.critrevon c.2008.08.003]
276. Ronco PM. Paraneoplastic glomerulopathies: new insights into an old entity. Kidney Int 1999; 56: 355-377 [PMID: 10411717 DOI: 10.1046/j.1523-1755.1999.00548.x]
277. Puolijoki H, Mustonen J, Pettersson E, Pasternack A, Lahdensuo A. Proteinuria and haematuria are frequently present in patients with lung cancer. Nephrol Dial Transplant 1989; 4: 947-950 [PMID: 2516885]
278. Ohara G, Satoh H, Kurishima K, Ohtsuka M, Hizawa N. Paraneoplastic nephrotic syndrome in patients with lung cancer. Intern Med 2009; 48: 1817-1820 [PMID: 19834274 DOI: 10.2169/internalmedicine.48.2089]
279. Wagrowska-Danilewicz M, Danilewicz M. Nephrotic syndrome and neoplasia: our experience and review of the literature. Pol J Pathol 2011; 62: 12-18 [PMID: 21574101]
280. Meyrier A, Delahousse M, Callard P, Rainfray M. Minimal change nephrotic syndrome revealing solid tumors. Nephron 1992; 61: 220-223 [PMID: 1321349 DOI: 10.1159/000186877]
281. Yacoub G, Kosseifi SG, Shah LS, Byrd RP, Roy TM. IgA nephropathy and small cell lung carcinoma. Tenn Med 2008; 101: 35-37, 40 [PMID: 18459646]
282. Lin FC, Chen JY, Yang AH, Chang SC. The association of non-small-cell lung cancer, focal segmental glomerulosclerosis, and platelet dysfunction. Am J Med Sci 2002; 324: 161-165 [PMID: 12240715 DOI: 10.1097/00000441-200209000-00008]
283. Tadokoro A, Ishii T, Takahama T, Watanabe N, Takano K, Kanaji N, Imataki O, Dobashi H, Bandoh S, Matsunaga T. Paraneoplastic focal segmental glomerulosclerosis in a patient with lung adenocarcinoma. Intern Med 2013; 52: 1953-1956 [PMID: 23994990]
284. Usalan C, Emri S. Membranoproliferative glomerulonephritis associated with small cell lung carcinoma. Int Urol Nephrol 1998; 30: 209-213 [PMID: 9607894]
285. Chiu KC, Tsai TC, Lin WT, Lee WJ, Su CC, Chen CY. Paraneoplastic polymyositis associated with crescentic glomerulonephritis. Ren Fail 2008; 30: 939-942 [PMID: 18925535 DOI: 10.1080/08860220802353918]
286. Lefaucheur C, Stengel B, Nochy D, Martel P, Hill GS, Jacquot C, Rossert J. Membranous nephropathy and cancer: Epidemiologic evidence and determinants of high-risk cancer association. Kidney Int 2006; 70: 1510-1517 [PMID: 16941021 DOI: 10.1038/sj.ki.5001790]
287. Wakashin M, Wakashin Y, Iesato K, Ueda S, Mori Y, Tsuchida H, Shigematsu H, Okuda K. Association of gastric cancer and nephrotic syndrome. An immunologic study in three patients. Gastroenterology 1980; 78: 749-756 [PMID: 6986318]
288. Costanza ME, Pinn V, Schwartz RS, Nathanson L. Carcinoembryonic antigen-Antibody complexes in a patient with colonic carcinoma and nephrotic syndrome. N Engl J Med 1973; 289: 520-522 [PMID: 4579334 DOI: 10.1056/NEJM197309062891007]
289. Pascal RR, Slovin SF. Tumor directed antibody and carcinoembryonic antigen in the glomeruli of a patient with gastric carcinoma. Hum Pathol 1980; 11: 679-682 [PMID: 6450154 DOI: 10.1016/S0046-8177(80)80082-7]
290. Sakamori Y, Kim YH, Okuda C, Togashi Y, Kinose D, Masago K, Mio T, Uji A, Mishima M. Two cases of cancerassociated retinopathy combined with small-cell lung cancer. Jpn J Clin Oncol 2011; 41: 669-673 [PMID: 21385760 DOI: 10.1093/jjco/hyr025]
291. Sawyer RA, Selhorst JB, Zimmerman LE, Hoyt WF. Blindness caused by photoreceptor degeneration as a remote effect of cancer. Am J Ophthalmol 1976; 81: 606-613 [PMID: 179323]
292. Jacobson DM, Thirkill CE, Tipping SJ. A clinical triad to diagnose paraneoplastic retinopathy. Ann Neurol 1990; 28: 162-167 [PMID: 2171418]
293. Savchenko MS, Goncharskaia MA, Skorikova EE, Eichmöller SB, Kushlinsky NE, Bazhin AV, Philippov PP. Autoantibodies against the Ca(2+)-binding protein recoverin in blood sera of patients with various oncological diseases. Oncol Lett 2012; 3: 377-382 [PMID: 22740915]
294. Ohguro H, Ogawa K, Maeda T, Maeda A, Maruyama I. Cancer-Associated retinopathy induced by both anti-recoverin and anti-hsc70 antibodies in vivo. Invest Ophthalmol Vis Sci 1999; 40: 3160-3167 [PMID: 10586938]
295. Weleber RG, Watzke RC, Shults WT, Trzupek KM, Heckenlively JR, Egan RA, Adamus G. Clinical and electrophysiologic characterization of paraneoplastic and autoimmune retinopathies associated with antienolase antibodies. Am J Ophthalmol 2005; 139: 780-794 [PMID: 15860281]
296. Kondo M, Sanuki R, Ueno S, Nishizawa Y, Hashimoto N, Ohguro H, Yamamoto S, Machida S, Terasaki H, Adamus G, Furukawa T. Identification of autoantibodies against TRPM1 in patients with paraneoplastic retinopathy associated with ON bipolar cell dysfunction. PLoS One 2011; 6: e19911 [PMID: 21611200 DOI: 10.1371/journal.pone.0019911]
297. Polans AS, Buczyl ko J, Crabb J, Palczewski K. A photoreceptor calcium binding protein is recognized by autoantibodies obtained from patients with cancer-Associated retinopathy. J Cell Biol 1991; 112: 981-989 [PMID: 1999465 DOI: 10.1083/jcb.112.5.981]
298. Polans AS, Witkowska D, Haley TL, Amundson D, Baizer L, Adamus G. Recoverin, a photoreceptor-specific calciumbinding protein, is expressed by the tumor of a patient with cancer-Associated retinopathy. Proc Natl Acad Sci USA 1995; 92: 9176-9180 [PMID: 7568096 DOI: 10.1073/pnas.92.20.9176]
299. Bazhin AV, Shifrina ON, Savchenko MS, Tikhomirova NK, Goncharskaia MA, Gorbunova VA, Senin II, Chuchalin AG, Philippov PP. Low titre autoantibodies against recoverin in sera of patients with small cell lung cancer but without a loss of vision. Lung Cancer 2001; 34: 99-104 [PMID: 11557119 DOI: 10.1016/S0169-5002(01)00212-4]
300. Savchenko MS, Bazhin AV, Shifrina ON, Demoura SA, Kogan EA, Chuchalin AG, Philippov PP. Antirecoverin autoantibodies in the patient with non-small cell lung cancer but without cancer-Associated retinopathy. Lung Cancer 2003; 41: 363-367 [PMID: 12928127 DOI: 10.1016/S0169-5002(03)00239-3]
301. Bazhin AV, De Smet C, Golovastova MO, Schmidt J, Philippov PP. Aberrant demethylation of the recoverin gene is involved in the aberrant expression of recoverin in cancer cells. Exp Dermatol 2010; 19: 1023-1025 [PMID: 20812967 DOI: 10.1111/j.1600-0625.2010.01126.x]
302. Suzuki T, Obara Y, Sato Y, Saito G, Ichiwata T, Uchiyama T. Cancer-Associated retinopathy with presumed vasculitis. Am J Ophthalmol 1996; 122: 125-127 [PMID: 8659589]
303. Matsuo S, Ohguro H, Ohguro I, Nakazawa M. Clinicopathological roles of aberrantly expressed recoverin in malignant tumor cells. Ophthalmic Res 2010; 43: 139-144 [PMID: 19887879 DOI: 10.1159/000253486]
304. Yu S, Ikeda T, Ikeda N, Mimura O, Sato K. Coloration of fundus lesions in bilateral diffuse uveal melanocytic proliferation. Jpn J Ophthalmol 2003; 47: 612-615 [PMID: 14636855 DOI: 10.1016/j.jjo.2003.09.003]
305. Gass JD, Gieser RG, Wilkinson CP, Beahm DE, Pautler SE. Bilateral diffuse uveal melanocytic proliferation in patients with occult carcinoma. Arch Ophthalmol 1990; 108: 527-533 [PMID: 2322154 DOI: 10.1001/archopht.1990.01070060075053]
306. Reddy S, Finger PT. Unilateral diffuse uveal melanocytic proliferation (DUMP). Br J Ophthalmol 2007; 91: 1726-1727 [PMID: 18024831 DOI: 10.1136/bjo.2007.116681]
307. ONeal KD, Butnor KJ, Perkinson KR, Proia AD. Bilateral diffuse uveal melanocytic proliferation associated with pancreatic carcinoma: A case report and literature review of this paraneoplastic syndrome. Surv Ophthalmol 2003; 48: 613-625 [PMID: 14609707 DOI: 10.1016/j.survophthal.2003.08.005]
308. Sen J, Clewes AR, Quah SA, Hiscott PS, Bucknall RC, Damato BE. Presymptomatic diagnosis of bronchogenic carcinoma associated with bilateral diffuse uveal melanocytic proliferation. Clin Experiment Ophthalmol 2006; 34: 156-158 [PMID: 16626431 DOI: 10.1111/j.1442-9071.2006.01145.x]
309. Mandelcorn E, McGuire K, Dixon W, Mandelcorn M. Ocular paraneoplastic syndrome: A case of bilateral diffuse uveal melanocytic proliferation. Retina 2009; 29: 1375-1376 [PMID: 19934829 DOI: 10.1097/IAE.0b013e3181b2106b]
310. Singh AD, Rundle PA, Slater DN, Rennie IG, Parsons A, McDonagh AJ. Uveal and cutaneous involvement in paraneoplastic melanocytic proliferation. Arch Ophthalmol 2003; 121: 1637-1640 [PMID: 14609926 DOI: 10.1001/archopht. 121.11.1637]
311. Trousseau A. Plegmasia alba dolens. Clinique medicale de l Hotel-Dieu de Paris, London. N Sydenham Soc 1865; 3: 94
312. Sack GH, Levin J, Bell WR. Trousseaus syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features. Medicine (Baltimore) 1977; 56: 1-37 [PMID: 834136 DOI: 10.1097/00005792-197756010-00001]
313. Varki A. Trousseaus syndrome: multiple definitions and multiple mechanisms. Blood 2007; 110: 1723-1729 [PMID: 17496204 DOI: 10.1182/blood-2006-10-053736]
314. Pineo GF, Brain MC, Gallus AS, Hirsh J, Hatton MW, Regoeczi E. Tumors, mucus production, and hypercoagulability. Ann N Y Acad Sci 1974; 230: 262-270 [PMID: 4522873 DOI: 10.1111/j.1749-6632.1974.tb14458.x]
315. Shao B, Wahrenbrock MG, Yao L, David T, Coughlin SR, Xia L, Varki A, McEver RP. Carcinoma mucins trigger reciprocal activation of platelets and neutrophils in a murine model of Trousseau syndrome. Blood 2011; 118: 4015-4023 [PMID: 21860019 DOI: 10.1182/blood-2011-07-368514]
316. Denko NC, Giaccia AJ. Tumor hypoxia, the physiological link between Trousseaus syndrome (carcinoma-induced coagulopathy) and metastasis. Cancer Res 2001; 61: 795-798 [PMID: 11221857]
317. Blom JW, Osanto S, Rosendaal FR. The risk of a venous thrombotic event in lung cancer patients: higher risk for adenocarcinoma than squamous cell carcinoma. J Thromb Haemost 2004; 2: 1760-1765 [PMID: 15456487 DOI: 10.1111/j.1538-7836.2004.00928.x]
318. Alderman CP, McClure AF, Jersmann HP, Scott SD. Continuous subcutaneous heparin infusion for treatment of Trousseaus syndrome. Ann Pharmacother 1995; 29: 710-713 [PMID: 8520087]
319. Liepman CI, Koerber JM, Mattson JC, Westley SJ, Smythe MA. Comparing methods of establishing the aPTT therapeutic range of heparin. Ann Pharmacother 2003; 37: 794-798 [PMID: 12773063 DOI: 10.1345/aph.1C162]
320. Zacharski LR, Loynes JT. Low-molecular-weight heparin in oncology. Anticancer Res 2003; 23: 2789-2793 [PMID: 12926114]
321. McCart GM, Kayser SR. Therapeutic equivalency of lowmolecular-weight heparins. Ann Pharmacother 2002; 36: 1042-1057 [PMID: 12022908 DOI: 10.1345/aph.10264]
322. Zöger M, Demarmels Biasiutti F, Wuillemin WA, Furlan M, Lämmle B. Subcutaneous low-molecular-weight heparin for treatment of Trousseaus syndrome. Ann Hematol 1997; 75: 165-167 [PMID: 9402851 DOI: 10.1007/s002770050336]
323. Walsh-McMonagle D, Green D. Low-molecular-weight heparin in the management of Trousseaus syndrome. Cancer 1997; 80: 649-655 [PMID: 9264346 DOI: 10.1002/(SICI)109 7-0142(19970815)80649: : AID-CNCR1: 43.0.CO; 2-I]
324. Stevenson JL, Choi SH, Varki A. Differential metastasis inhibition by clinically relevant levels of heparins-correlation with selectin inhibition, not antithrombotic activity. Clin Cancer Res 2005; 11: 7003-7011 [PMID: 16203794 DOI: 10.1158/1078-0432.CCR-05-1131]
325. Ludwig RJ, Alban S, Bistrian R, Boehncke WH, Kaufmann R, Henschler R, Gille J. The ability of different forms of heparins to suppress P-selectin function in vitro correlates to their inhibitory capacity on bloodborne metastasis in vivo. Thromb Haemost 2006; 95: 535-540 [PMID: 16525583]
326. Imberti D, Ageno W, Manfredini R, Fabbian F, Salmi R, Duce R, Gallerani M. Interventional treatment of venous thromboembolism: A review. Thromb Res 2012; 129: 418-425 [PMID: 22119500 DOI: 10.1016/j.thromres.2011.11.003]